Grace Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Grace Therapeutics, Inc. (GRCE) reported Increase Decrease In Operating Lease Liability of $0 for the 12-month period ending 2025-03-31, per its 10-K filed 2025-06-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2025-06-23
- Grace Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-03-31 was $0.00.
- Grace Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2024-12-31 was $0.00.
- Grace Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2024-09-30 was $0.00.
- Grace Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2024-06-30 was $0.00.
- Grace Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was $0.00.
- Grace Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$23.00K.
- Grace Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was $0.00.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | $0.00 derived: sum of 2 quarters · filed 2025-06-23 | $0.00 derived: sum of 3 quarters · filed 2025-06-23 | $0.00 10-K · filed 2025-06-23 |
| 2024-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $0.00 derived: sum of 2 quarters · filed 2025-02-13 | $0.00 10-Q · filed 2025-02-13 | $0.00 derived: sum of 4 quarters · filed 2025-06-23 |
| 2024-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 3 quarters · filed 2025-06-23 | $0.00 derived: sum of 4 quarters · filed 2025-06-23 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-09 | $0.00 derived: sum of 2 quarters · filed 2025-06-23 | $0.00 derived: sum of 3 quarters · filed 2025-06-23 | -$10.00K derived: sum of 4 quarters · filed 2025-06-23 |
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | $0.00 derived: sum of 2 quarters · filed 2025-06-23 | -$10.00K derived: sum of 3 quarters · filed 2025-06-23 | -$23.00K 10-K · filed 2025-06-23 |
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | -$10.00K derived: sum of 2 quarters · filed 2025-02-13 | -$23.00K 10-Q · filed 2025-02-13 | -$23.00K derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-09-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-13 | -$23.00K 10-Q · filed 2024-11-13 | -$23.00K derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$13.00K 10-Q · filed 2024-08-09 | -$13.00K derived: sum of 2 quarters · filed 2024-08-09 | ||
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | $0.00 10-K · filed 2024-06-21 | ||
| 2022-12-31 | $0.00 10-Q · filed 2024-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |